The Defense Health Agency established a formal hormone screening pathway for female service members. Understand how this new guidance impacts military health.
The Defense Health Agency's newly structured hormone screening pathway is a clinical framework designed to evaluate endocrine function, energy availability and menstrual health during the annual military Periodic Health Assessment. A female service member sitting in a clinic waiting room knows that reporting fatigue or menstrual irregularity usually leads to fragmented answers. She needs a unified plan to stay capable. The military medical system has traditionally lacked a standardized approach for female hormonal optimization until now.
On September 2, 2026, the Defense Health Agency issued clinical guidance establishing a structured pathway for evaluating hormonal and energy availability concerns in female service members. DHA Director Vice Adm. Darin Via signed the guidance to establish uniform clinical pathways across the enterprise. The guidance was presented as part of a broader Department of Defense effort to identify and manage hormone and energy availability problems. The ultimate goal is to support overall military readiness and operational capability.
The female pathway differed from the mandatory testosterone blood testing policy described for male service members aged 30 and older. For women, the initial step was an annual clinical screen during the Periodic Health Assessment rather than an automatic testosterone test. The guidance identified fatigue, musculoskeletal pain and menstrual changes as signs that could prompt targeted evaluation for Relative Energy Deficiency in Sport. RED-S refers to inadequate energy availability relative to the demands of training and daily activity.
This condition carries possible effects on menstrual function, bone health and physical performance. In the DHA pathway, the initial clinical concern leads to additional assessment rather than automatic laboratory testing. If the initial assessment did not indicate concern for RED-S, the guidance required no further evaluation under that pathway. If concern remained, active duty service members could be referred to their primary care managers for further assessment and treatment.
In our experience, shifting priorities from active duty requirements to veteran life takes deliberate effort. Trying to maintain fitness years after leaving service required a completely new mindset. The goal changed from immediate tactical readiness to healthy aging and longevity. I learned that connecting short term performance with long term health, focusing on mobility and cardiovascular function, was the real key to staying capable.
The RED-S evaluation process relies on established clinical instruments. The next stage could include the Low Energy Availability in Females Questionnaire and the International Olympic Committee's RED-S Clinical Assessment Tool Version 2. That assessment classified risk into four distinct categories. These ranged from low risk with unrestricted training to high risk where limited duty, medical profiling or hospitalization could be necessary.
The policy was framed by Defense Secretary Pete Hegseth as a readiness initiative focused on preserving service members' health and their "biological foundation" for military duties. The Pentagon's stated rationale was to identify and manage hormone related problems rather than to provide performance enhancing treatment. The inclusion of RED-S tools connected military medicine with established sports medicine concepts involving training demands. In practical terms, the pathway gave clinicians a framework for deciding when a symptom should be monitored or investigated.
To understand this new clinical pathway, service members need to know what normal physiological function looks like. The guidance noted that menstrual cycles longer than 35 days fall outside the standard baseline. Cycles extending past this duration could prompt targeted RED-S assessment. For prolonged or absent menstruation, pregnancy testing and additional hormone testing could be ordered when clinically indicated.
When RED-S was suspected, clinicians could order specific laboratory evaluations to assess baseline function. These could include a complete blood count, a comprehensive metabolic panel and ferritin. Clinicians might also test iron studies, vitamin B12 and thyroid stimulating hormone levels. These objective lab markers give military physicians a comprehensive view of overall physiological stress.
Female service members aged 35 and older who reported clinically significant perimenopause or menopause symptoms were to be assessed. Providers evaluated whether these symptoms affected operational duties and quality of life. If symptoms affected duties or quality of life, the provider was directed to refer her to a midlife transition specialist. This specialized approach ensures proper education, evaluation and clinical care.
The guidance identified several possible specialists to handle these cases. Referrals could be made to an obstetrician-gynecologist, a certified nurse midwife or an endocrinologist. A women's health nurse practitioner or a trained primary care provider could also manage these cases. This approach treated menopause related care as a clinical and functional issue rather than an automatic justification for hormone treatment.
When considering hormone therapies, the guidance relied on the 2019 Global Consensus Position Statement on testosterone therapy for women. The reported testosterone option was strictly limited to postmenopausal women with distressing low sexual desire. This condition is formally known as hypoactive sexual desire disorder, or HSDD. This intervention was only considered after other possible causes had been thoroughly assessed.
If testosterone treatment was selected, it would be strictly off-label. The dose was limited to a low amount equivalent to one-tenth of an FDA-approved male 1% testosterone cream or gel. The stated goal was to keep levels within the normal premenopausal female range. The guidance did not aim to produce supraphysiologic concentrations.
The monitoring schedule reflects a highly cautious approach to returning patients to their baseline safely. The guidance recommended checking testosterone levels three to six weeks after treatment began or after a dose increase. Treatment was to be stopped after six months if there was no demonstrated benefit. For women who continued treatment, the guidance called for clinical evaluation and testosterone testing every four to six months.
The document cautioned that safety data for physiologic testosterone treatment in women did not extend beyond 24 months. This limitation argues against indefinite treatment without periodic reassessment. The guidance also urged caution for women with hormone-sensitive breast cancer or high cardiometabolic risk. Proper clinical evaluation ensures you maintain healthy body composition and operational capability safely.
While the initial announcement provided a clear framework, the policy implementation status quickly changed. On September 3, the Pentagon removed the document from its website. The newly published guidance was temporarily rescinded to allow for updates. An interim guidance on testosterone deficiency screening remained in effect at that time.
As of September 4, 2026, the specific female screening provisions were not permanently settled. The September 2 document therefore should not be treated as a final policy. Its female screening and treatment provisions may be revised when the Pentagon issues updated guidance. Readers should verify the current policy through their military treatment facility before assuming that every provision remains active.
The broader Pentagon initiative announced in July 2026 remains relevant to overall military health strategy. That earlier directive mandated testosterone deficiency screening for male service members aged 30 and older. It also made optional screening available to younger warfighters. The September guidance was originally intended to operationalize both the male testosterone screening and female hormonal optimization pathways.
BattleVet provides research backed guidance on military health, but we do not provide medical advice. This article is for educational purposes only. Veterans and active duty personnel must consult a qualified physician or VA provider before self diagnosing. Individual health decisions should always be made with a licensed medical professional.
If you are an active duty service member, prepare to discuss your health presentation clearly. Track menstrual changes, unusual fatigue, persistent musculoskeletal pain or changes in sexual function before your appointment. Ask your clinician what specific condition is being evaluated and what testing is clinically indicated. A clinical screen during the Periodic Health Assessment does not establish a diagnosis on its own.
Women considering treatment should view testosterone as a narrowly indicated option. It is not a general treatment for athletic performance, mood, cognition or nonspecific hormonal imbalances. Data regarding its usefulness in premenopausal women remains highly limited. A service member's fatigue or sexual health concerns should not be reduced to a single hormone result.
Veterans experiencing related symptoms should proactively speak to their VA clinicians. The Defense Health Agency pathway applies to military healthcare rather than automatically creating a treatment entitlement for veterans. The sources reviewed describe an active duty and reserve screening policy. Therefore, veterans should ask about appropriate evaluation rather than assume this specific pathway governs their care.
Navigating the military healthcare system requires accurate documentation of your personal health metrics. The most crucial aspect of understanding this new hormone screening concept is that targeted clinical assessment always precedes treatment. Your key takeaway is to start tracking your daily energy levels, sleep quality and menstrual cycle duration right now to provide clear data at your next health assessment.
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
The VA Oracle health record contract ceiling has risen to $27 billion. Learn how this modernization project impacts local medical care and your health records.
The U.S. Army updated its Holistic Health and Fitness doctrine to standardize training and shift from reactive clinics to proactive unit performance teams.
The Army is addressing national youth fitness declines through the Future Soldier Preparatory Course and updated physical standards. Learn what the data means.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet